Cytomx Therapeutics Stock Investor Sentiment

CTMX Stock  USD 2.18  0.01  0.46%   
Slightly above 68% of CytomX Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding CytomX Therapeutics suggests that many traders are alarmed. CytomX Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in CytomX Therapeutics. The current market sentiment, together with CytomX Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use CytomX Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Panic Vs Confidence

32

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use CytomX Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward CytomX Therapeutics.
CytomX Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of CytomX daily returns and investor perception about the current price of CytomX Therapeutics as well as its diversification or hedging effects on your existing portfolios.

CytomX Historical Sentiment

Although CytomX Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding CytomX, such as negative comments on social media and news outlets, may cause fear in the market and push CytomX Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of CytomX.
  

CytomX Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards CytomX Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

CytomX Therapeutics Historical Investor Sentiment

Investor biases related to CytomX Therapeutics' public news can be used to forecast risks associated with an investment in CytomX. The trend in average sentiment can be used to explain how an investor holding CytomX can time the market purely based on public headlines and social activities around CytomX Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
CytomX Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for CytomX Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average CytomX Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on CytomX Therapeutics.
2 days ago at news.google.com         
Q1 2024 Earnings Forecast for CytomX Therapeutics, Inc. Issued By HC Wainwright - MarketBeat
Google News at Macroaxis
3 days ago at news.google.com         
Disposition of 109768 shares by Sean McCarthy of CytomX Therapeutics at 1.5749 subject to Rule 16b-3
Google News at Macroaxis
few days ago at news.google.com         
Insider Selling CytomX Therapeutics, Inc. CEO Sells 20223 Shares of Stock - Defense World
Google News at Macroaxis
six days ago at news.google.com         
CytomX Therapeutics Welcomes New Director and Updates Bylaws - TipRanks.com - TipRanks
Google News at Macroaxis
over a week ago at investing.com         
Disposition of 12795 shares by Marcia Belvin of CytomX Therapeutics at 2.0855 subject to Rule 16b-3
Investing News at Macroaxis
over a week ago at www.macroaxis.com         
Insider Trading
Macroaxis News
over a week ago at www.macroaxis.com         
Disposition of 6562 shares by Landau Jeffrey B of CytomX Therapeutics at 2.0855 subject to Rule 16b-...
Macroaxis News
over a week ago at news.google.com         
Research Analysts Issue Forecasts for CytomX Therapeutics, Inc.s FY2028 Earnings - Defense World
Google News at Macroaxis
over a week ago at news.google.com         
CytomX Therapeutics, Inc. Sees Significant Growth in Short Interest - MarketBeat
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
CytomX Therapeutics Full Year 2023 Earnings Revenues Beat Expectations, EPS Lags
Yahoo News
over two weeks ago at investing.com         
Jefferies lifts CytomX Therapeutics stock target to 2.50, maintains hold
Investing News at Macroaxis
over two weeks ago at investing.com         
CytomX shares target cut to 3.25 from 3.25 by BMO Capital
Investing News at Macroaxis
over two weeks ago at seekingalpha.com         
CytomX stock falls as Bristol Myers cancer therapy deal
seekingalpha News
over two weeks ago at insidermonkey.com         
CytomX Therapeutics, Inc. Q4 2023 Earnings Call Transcript
insidermonkey News
over two weeks ago at finance.yahoo.com         
CytomX Therapeutics Lags Q4 Earnings Estimates
Yahoo News
Far too much social signal, news, headlines, and media speculation about CytomX Therapeutics that are available to investors today. That information is available publicly through CytomX media outlets and privately through word of mouth or via CytomX internal channels. However, regardless of the origin, that massive amount of CytomX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CytomX Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CytomX Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CytomX Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CytomX Therapeutics alpha.

CytomX Therapeutics Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
Acquisition by Matthew Young of 20000 shares of CytomX Therapeutics subject to Rule 16b-3
01/08/2024
2
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activ...
01/24/2024
3
Q1 2021 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus.com
02/06/2024
4
Even after rising 12 percent this past week, CytomX Therapeutics shareholders are still down 85 percent over the past five years
02/27/2024
5
Acquisition by Timothy Shannon of 14000 shares of CytomX Therapeutics subject to Rule 16b-3
02/28/2024
6
CytomX Therapeutics Inc earnings missed by 0.03, revenue fell short of estimates
02/29/2024
7
CytomX Therapeutics to Release Quarterly Earnings on Monday
03/05/2024
8
CytomX Therapeutics Inc Reports 2023 Financial Results and Provides Pipeline Update
03/11/2024
9
Jefferies lifts CytomX Therapeutics stock target to 2.50, maintains hold
03/12/2024
10
CytomX Therapeutics Full Year 2023 Earnings Revenues Beat Expectations, EPS Lags
03/13/2024
11
Disposition of 6562 shares by Landau Jeffrey B of CytomX Therapeutics at 2.0855 subject to Rule 16b-3
03/19/2024
12
Insider Trading
03/20/2024
13
CytomX Therapeutics Welcomes New Director and Updates Bylaws - TipRanks.com - TipRanks
03/22/2024
14
Q1 2024 Earnings Forecast for CytomX Therapeutics, Inc. Issued By HC Wainwright - MarketBeat
03/27/2024
When determining whether CytomX Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytomX Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomx Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomx Therapeutics Stock:
Check out CytomX Therapeutics Hype Analysis, CytomX Therapeutics Correlation and CytomX Therapeutics Performance.
For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for CytomX Stock analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Revenue Per Share
1.371
Quarterly Revenue Growth
0.322
Return On Assets
(0.02)
Return On Equity
(54.75)
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.